Home
CNTA
CNTA News

Latest Centessa Pharmaceuticals plc (CNTA) News on October 31, 2025

Centessa Pharmaceuticals (CNTA): Reviewing Valuation After 46% Three-Month Share Price Surge

Simply Wall St.

14 days ago

Centessa Pharmaceuticals (CNTA): Reviewing Valuation After 46% Three-Month Share Price Surge

MT Newswires

2 months ago

European Equities Traded in the US as American Depositary Receipts Decline Thursday

Centessa Pharmaceuticals Receives FDA Clearance for New Drug ORX142, Initiates Phase 1 Study

Insider Monkey

4 months ago

Centessa Pharmaceuticals Receives FDA Clearance for New Drug ORX142, Initiates Phase 1 Study

Centessa Pharmaceuticals plc's (NASDAQ:CNTA) Intrinsic Value Is Potentially 99% Above Its Share Price

Simply Wall St.

4 months ago

Centessa Pharmaceuticals plc's (NASDAQ:CNTA) Intrinsic Value Is Potentially 99% Above Its Share Price

MT Newswires

4 months ago

European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday

Centessa announces clearance of IND for ORX142

TipRanks

4 months ago

Centessa announces clearance of IND for ORX142

Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

4 months ago

Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?

MT Newswires

4 months ago

Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

GlobeNewswire

4 months ago

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet

Zacks

5 months ago

Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet

MT Newswires

5 months ago

Needham Initiates Centessa Pharmaceuticals ADR at Buy With $35 Price Target

MT Newswires

5 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $699,111, According to a Recent SEC Filing

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

MT Newswires

6 months ago

Centessa Pharmaceuticals Posts Revenue, Q1 Net Loss Narrows

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

GlobeNewswire

6 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz

TipRanks

6 months ago

Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz

MT Newswires

6 months ago

Chardan Initiates Centessa Pharmaceuticals at Buy With $30 Price Target

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

Insider Monkey

6 months ago

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

MT Newswires

6 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $681,576, According to a Recent SEC Filing

MT Newswires

7 months ago

Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

GlobeNewswire

7 months ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

GlobeNewswire

8 months ago

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

MT Newswires

9 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $588,944, According to a Recent SEC Filing

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

9 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?

Insider Monkey

10 months ago

Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?

Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?

Insider Monkey

10 months ago

Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

GlobeNewswire

10 months ago

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

MT Newswires

10 months ago

TD Cowen Initiates Centessa Pharmaceuticals ADR at Buy

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Simply Wall St.

10 months ago

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate

MT Newswires

10 months ago

Centessa Pharmaceuticals Secures Loan Facility, Repays Debt

MT Newswires

10 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $959,057, According to a Recent SEC Filing

Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?

Insider Monkey

10 months ago

Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?

MT Newswires

10 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $284,010, According to a Recent SEC Filing

MT Newswires

a year ago

Centessa Pharmaceuticals Insider Sold Shares Worth $1,615,255, According to a Recent SEC Filing

MT Newswires

a year ago

Morgan Stanley Lifts Price Target on Centessa Pharmaceuticals to $27 From $26, Keeps Overweight Rating

Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing

BioPharma Dive

a year ago

Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing

MT Newswires

a year ago

Centessa Pharmaceuticals' Q3 Loss Widens

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

GlobeNewswire

a year ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

MT Newswires

a year ago

Centessa Pharmaceuticals Insider Sold Shares Worth $863,727, According to a Recent SEC Filing

Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech

Insider Monkey

a year ago

Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech

Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments

Insider Monkey

a year ago

Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

GlobeNewswire

a year ago

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

MT Newswires

a year ago

Centessa Pharmaceuticals Shares Rise After Upgrade From Morgan Stanley

MT Newswires

a year ago

Morgan Stanley Upgrades Centessa Pharmaceuticals to Overweight From Equalweight, Adjusts PT to $26 From $11

MT Newswires

a year ago

Update: B. Riley Initiates Centessa Pharmaceuticals at Buy With $33 Price Target

MT Newswires

a year ago

B. Riley Initiates Centessa Pharmaceuticals at Buy

MT Newswires

a year ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Centessa Pharmaceuticals Prices Upsized $225 Million Public Offering

MT Newswires

a year ago

Centessa Pharmaceuticals Insider Sold Shares Worth $2,891,823, According to a Recent SEC Filing

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

GlobeNewswire

a year ago

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

MT Newswires

a year ago

Centessa Pharmaceuticals Files Mixed Shelf; Launches $150 Million Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

GlobeNewswire

a year ago

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity

Investor's Business Daily

a year ago

Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity

MT Newswires

a year ago

Top Midday Gainers

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Centessa Pharmaceuticals Shares Up After Drug Trial Found to Restore Wakefulness in Subjects

Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers

Benzinga

a year ago

Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers

Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity

Investor's Business Daily

a year ago

Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity

Investors are waking up to Centessa’s sleepiness drug

BioPharma Dive

a year ago

Investors are waking up to Centessa’s sleepiness drug

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

GlobeNewswire

a year ago

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

MT Newswires

a year ago

Centessa Pharmaceuticals Insider Sold Shares Worth $375,000, According to a Recent SEC Filing

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

GlobeNewswire

a year ago

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ...

GuruFocus.com

a year ago

Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ...

MT Newswires

a year ago

Centessa Pharmaceuticals Insider Sold Shares Worth $573,905, According to a Recent SEC Filing

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

a year ago

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Centessa Pharmaceuticals plc's (NASDAQ:CNTA) high institutional ownership speaks for itself as stock continues to impress, up 18% over last week

Simply Wall St.

a year ago

Centessa Pharmaceuticals plc's (NASDAQ:CNTA) high institutional ownership speaks for itself as stock continues to impress, up 18% over last week

MT Newswires

a year ago

Centessa Pharmaceuticals' Q2 Net Loss Widens

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

GlobeNewswire

a year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Are Medical Stocks Lagging Stryker (SYK) This Year?

Zacks

a year ago

Are Medical Stocks Lagging Stryker (SYK) This Year?

MT Newswires

a year ago

Oppenheimer Initiates Centessa Pharmaceuticals at Outperform Rating With $14 Price Target

Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade

MT Newswires

a year ago

Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $11 From $8, Maintains Equalweight Rating

MT Newswires

a year ago

Centessa Pharmaceuticals Appoints John Crowley as CFO

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

GlobeNewswire

a year ago

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

3 Major Product Releases at 3Shape Discover Event

PR Newswire

a year ago

3 Major Product Releases at 3Shape Discover Event

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

GlobeNewswire

a year ago

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029

GlobeNewswire

a year ago

Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029

Advantech Releases FWA-3051, The Latest 1U Rackmount Edge Networking Solution with Intel® Xeon® D-2700/2800 Series

PR Newswire

a year ago

Advantech Releases FWA-3051, The Latest 1U Rackmount Edge Networking Solution with Intel® Xeon® D-2700/2800 Series

EXCLUSIVE: Sunlight Creates Love Note Projections In New Fred Jewelry Collection

WWD

a year ago

EXCLUSIVE: Sunlight Creates Love Note Projections In New Fred Jewelry Collection

Hydrogen Storage Market Set to Hit $6.8 Billion by 2031, registering a solid CAGR of 23% - Exclusive Report by Coherent Market Insights

GlobeNewswire

a year ago

Hydrogen Storage Market Set to Hit $6.8 Billion by 2031, registering a solid CAGR of 23% - Exclusive Report by Coherent Market Insights

Shake Shack (SHAK) Rose after Strong Q4 Results

Insider Monkey

a year ago

Shake Shack (SHAK) Rose after Strong Q4 Results

Flash News: OKX to List Ultiverse's Token on its Perpetual Futures Market, Expanding Trading Options

GlobeNewswire

a year ago

Flash News: OKX to List Ultiverse's Token on its Perpetual Futures Market, Expanding Trading Options

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)

Zacks

a year ago

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

GlobeNewswire

a year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

MT Newswires

2 years ago

Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

GlobeNewswire

2 years ago

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

MT Newswires

2 years ago

Centessa Pharmaceuticals Eyes $100 Million in ADS Offering

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

GlobeNewswire

2 years ago

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

GlobeNewswire

2 years ago

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

GuruFocus.com

2 years ago

Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

GlobeNewswire

2 years ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares

GuruFocus.com

2 years ago

Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares

Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m

Simply Wall St.

2 years ago

Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

GlobeNewswire

2 years ago

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

GlobeNewswire

2 years ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Earnings Beat: Harmonic Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.

2 years ago

Earnings Beat: Harmonic Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Share on Social Networks: